External glucocorticosteroids: selection criteria in terms ofefficacy and safety



Cite item

Full Text

Abstract

The article describes mechanisms of action as well as indications and adverse effects of topical glucocorticosteroids. It examines
the pharmacological and pharmacokinetic properties of fluticasone propionate, an efficient external glucocorticosteroid having a
high safety level and good cosmetic properties. The data of controlled Russian and international studies of the efficacy and safety
of fluticasone propionate for the treatment of psoriasis, atopic dermatitis and eczema.

References

  1. Sterry W., Paus R., Burgdorf W.. Dermatology. Thieme clinical companions. Germany, 2006, p. 596-599.
  2. Моисеев С.В. Флютиказона пропионат (Кутивейт) в лечении заболеваний кожи. Клин. фаpмакол. и теpапия 1997; 6: 4: 18-20.
  3. Shaw R. Pharmacology of fluticasone propionate. Respir Med 1994; 88: (Suppl A): 5-8.
  4. Lee F.W. Nystrom D.D. Kooce W. Comparison of the percutaneous absorption of fluticasone 17-propionate from cream and ointment formulation in rats. Parm Res 1989; 6 Suppl:S106.
  5. De Bosscher K., Van den Berghe W. The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein- 1:Molecular mtchanisms for gene repression. Endoct Rev 2003; 24: 488-522.
  6. Johson M. Anti-inflammatory properties of fluticasone propionate. Int Arch Allergy Immunol 1995; 107: 439-440.
  7. Spencer C., Wisman L. Topical fluticasone propionate. A review of its pharmacological properties and therapeutic use in treatment of dermatological disorders. BioDrugs 1997; 7 (4): 318-334.
  8. Tan CY, Marks R, Payne P. Comparison of xeroradiographic and ultrasound detection of corticosteroid induced dermal thinning. J Invest Dermatol 1981; 76: 126-128.
  9. Roeder M. Schallerb M. Schäfer-Kortingc H.C. Kortinga Safety and Efficacy of FluticasonePropionate in the Topical Treatment of Skin Diseases Skin Pharmacol Physiol 2005; 18: 3-11.
  10. James M. A randomized, double-blind, multicenter trial comparing fluticasone propionate cream, 0.1%, applied twice daily for 4 weeks in the treatment of psoriasis. Cutis 1996; 67: 2-9.
  11. Nurnberger FG. A comparison of fluticasone propionate ointment, 0.005%, and hydrocortisone-17-butyrate ointment, 0.1%, in the treatment of psoriasis. Cutis 1996; 57: 39-44.
  12. Roberts DT. Comparison of fluticasone propionate ointment, 0.005%, and betamethasone-17,21-dipropionate ointment, 0.05%, in the treatment of psoriasis. Cutis 1996; 57: 27-31.
  13. Lebwohl MG, Tan MH, Meador SL, Singer G. Limited application of fluticasone propionate ointment, 0.005% on patients with psoriasis of the face and intertriginous areas. J Am Acad Dermatol 2001; 44: 77-82.
  14. Hachem JP, De Paepe K, Vanpee E. et al. Efficacy of topical corticosteroids in nickel-induced contact allergy. Clin Exp Dermatol 2002; 27: 47-50.
  15. Lebwohl M. Efficacy and safety of fluticasone propionate ointment, 0.005%, in the treatmentof eczema. Cutis 1996; 57: 62-68.
  16. Tan MH, Lebwohl M, Esser AC, Wei H. The penetration of 0.005% fluticasone propionate ointment in eyelid skin. J Am Acad Dermatol 2001; 45: 392-396.
  17. Tan MH, Meador SL, Singer G, Lebwohl MG. An open-label study of the safety and efficacy of limited application of fluticasone propionate ointment, 0.005% in patients with atopic dermatitis of the face and intertriginous areas. Int J Dermatol 2002; 41: 804-809.
  18. Tharp MD. A comparison of twice-daily and once-daily administration of fluticasone propionate cream, 0.05%, in the treatment of eczema. Cutis 1996; 57: 19.
  19. Wolkerstorfer A, Strobos MA, Glazenburg EJ,Mulder PG, Oranje AP. Fluticasone propionate 0.05% cream once daily versus clobetasone butyrate 0.05% cream twice daily in children with atopic dermatitis. J Am Acad Dermatol 1998; 39: 226-231.
  20. Pei AY, Chan HH, Ho KM. The effectiveness of wet wrap dressings using 0.1% mometasonefuroate and 0.005% fluticasone propionate ointments in the treatment of moderate to severe atopic dermatitis in children. Pediatr Dermatol 2001; 18: 343-348.
  21. Wolkerstorfer A, Visser RL, De Waard van derSpek FB, Mulder PG, Oranje AP. Efficacy and safety of wet-wrap dressings in children with severe atopic dermatitis: Influence of corticosteroid dilution. Br J Dermatol 2000; 143: 999-1004.
  22. Berth-Jones J, Damstra RJ, Golsch S, Livden JK, Van Hooteghem O, Allegra F, Parker CA, Multinational Study Group: Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis. BMJ 2003; 326: 1367-1373.
  23. Hachem JP, De Paepe K, Vanpee E, Kaufman L, Rogiers V, Roseeuw D. Combination therapy improves the recovery of the skin barrier function: An experimental model using a contact allergy patch test combined with TEWL measurements. Dermatology 2001; 202: 314-319.
  24. Hanifin J, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol 2002; 147: 528-537.
  25. Van Der Meer JB, Glazenburg EJ, Mulder PG,Eggink HF, Coenraads PJ: The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. Br J Dermatol 1999; 140: 1114-1121.
  26. Kirkup ME, Birchall NM, Weinberg EG, Helm K, Kennedy CT. Acute and maintenance treatment of atopic dermatitis in children - Two comparative studies with fluticasone propionate (0.05%) cream. J Dermatol Treat 2003; 14: 141-148.
  27. Иванов О.Л., Белоусова Т.А. Кутивейт - активный и безопасный топический кортикостероид. Тез. докладов V Российского национального конгресса «Человек и лекарство». М., 1998: 489.

Copyright (c) 2010 Belousova T.A., Goryachkina M.V., Belousova T.A., Goryachkina M.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 60448 от 30.12.2014.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies